These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 11704839

  • 1. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
    Ruiz de Almodóvar C, Ruiz-Ruiz C, Muñoz-Pinedo C, Robledo G, López-Rivas A.
    Oncogene; 2001 Oct 25; 20(48):7128-33. PubMed ID: 11704839
    [Abstract] [Full Text] [Related]

  • 2. Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells.
    Sarker M, Ruiz-Ruiz C, Robledo G, López-Rivas A.
    Oncogene; 2002 Jun 20; 21(27):4323-7. PubMed ID: 12082620
    [Abstract] [Full Text] [Related]

  • 3. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
    Walczak H, Bouchon A, Stahl H, Krammer PH.
    Cancer Res; 2000 Jun 01; 60(11):3051-7. PubMed ID: 10850456
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 01; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 5. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
    Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ, Lee MS.
    Oncogene; 2002 May 09; 21(20):3139-48. PubMed ID: 12082629
    [Abstract] [Full Text] [Related]

  • 6. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 7. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 8. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK.
    Cancer Res; 2003 Apr 01; 63(7):1712-21. PubMed ID: 12670926
    [Abstract] [Full Text] [Related]

  • 9. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 10. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells.
    Ruiz-Ruiz C, López-Rivas A.
    Biochem J; 2002 Aug 01; 365(Pt 3):825-32. PubMed ID: 11936954
    [Abstract] [Full Text] [Related]

  • 11. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
    Izeradjene K, Douglas L, Tillman DM, Delaney AB, Houghton JA.
    Cancer Res; 2005 Aug 15; 65(16):7436-45. PubMed ID: 16103097
    [Abstract] [Full Text] [Related]

  • 12. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 13. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells.
    Hao JH, Yu M, Liu FT, Newland AC, Jia L.
    Cancer Res; 2004 May 15; 64(10):3607-16. PubMed ID: 15150119
    [Abstract] [Full Text] [Related]

  • 14. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
    Kim EJ, Suliman A, Lam A, Srivastava RK.
    Int J Oncol; 2001 Jan 15; 18(1):187-94. PubMed ID: 11115558
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

  • 17. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N, El-Deiry WS.
    Neoplasia; 2002 Dec 01; 4(6):551-7. PubMed ID: 12407450
    [Abstract] [Full Text] [Related]

  • 18. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 19. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C, King DL, Norris JS.
    Cancer Gene Ther; 2002 Feb 15; 9(2):164-72. PubMed ID: 11857034
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.